Premature Ejaculation Treatment

A Global Strategic Business Report

MCP14184

RESEARCH STATS

DATE

MAR 2023

COMPANIES

31

TABLES

123

189

EDITION

7

PRICE

USD 4950

CODE

MCP14184

*Engagement stats are ongoing and dynamic

QUESTIONNAIRE EXECUTIVES DATA ROOM MARKETGLASS^TM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

$500/Month/User. Extra Users @ $100/Month/User
Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

REQUEST A TRIAL

PREMIUM

$1000/Month/User. Extra Users @ $100/Month/User
Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

REQUEST A TRIAL

ENTERPRISE

$2500/Month/User. Extra Users @ $150/Month/User
Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

REQUEST A TRIAL

HIGHLIGHTS & REPORT INDEX

What`s New?

» Special discussions on the global economic climate and market sentiment
» Coverage on global competitiveness and key competitor percentage market shares
» Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass™ research platform
» Complimentary updates for one year
» Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US$6 trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Premature Ejaculation Treatment Market to Reach $4 Billion by 2030
The global market for Premature Ejaculation Treatment estimated at US$2.2 Billion in the year 2022, is projected to reach a revised size of US$4 Billion by 2030, growing at aCAGR of 7.4% over the period 2022-2030. Selective Serotonin Reuptake Inhibitors (SSRIs), one of the segments analyzed in the report, is projected to record 6.9% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Tricyclic Antidepressant segment is estimated at 8.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $678.4 Million, While China is Forecast to Grow at 6.9% CAGR
The Premature Ejaculation Treatment market in the U.S. is estimated at US$678.4 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$686.5 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 6.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

SELECT PLAYERS

Absorption Pharmaceuticals Inc.; Allergan PLC; AstraZeneca PLC; Bayer AG; Eli Lilly and Company; GlaxoSmithKline PLC; Innovus Pharmaceuticals Inc.; Merck & Co., Inc.; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.

SEGMENTS

» Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors, Other Drug Classes) » Route of Administration (Oral, Topical)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

World Market Trajectories

Premature Ejaculation Treatment – Global Key Competitors Percentage Market Share in 2022 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 31 Players Worldwide in 2022 (E)

Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

World Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR

World Historic Review for Premature Ejaculation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

World 16-Year Perspective for Premature Ejaculation Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030

World Recent Past, Current & Future Analysis for Selective Serotonin Reuptake Inhibitors (SSRIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR

World Historic Review for Selective Serotonin Reuptake Inhibitors (SSRIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

World 16-Year Perspective for Selective Serotonin Reuptake Inhibitors (SSRIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

World Recent Past, Current & Future Analysis for Tricyclic Antidepressant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR

World Historic Review for Tricyclic Antidepressant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

World 16-Year Perspective for Tricyclic Antidepressant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

World Recent Past, Current & Future Analysis for Topical Anesthetic Agent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR

World Historic Review for Topical Anesthetic Agent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

World 16-Year Perspective for Topical Anesthetic Agent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

World Recent Past, Current & Future Analysis for Phosphodiesterase Type 5 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR

World Historic Review for Phosphodiesterase Type 5 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

World 16-Year Perspective for Phosphodiesterase Type 5 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR

World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR

World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR

World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

World 16-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

World Premature Ejaculation Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES

Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)

USA Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

USA Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

USA 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2023 & 2030

USA Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

USA Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

USA 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2023 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Canada Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Canada 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2023 & 2030

Canada Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Canada Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Canada 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2023 & 2030

JAPAN

Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)

Japan Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Japan Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Japan 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2023 & 2030

Japan Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Japan Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Japan 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2023 & 2030

CHINA

Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)

China Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

China Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

China 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2023 & 2030

China Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

China Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

China 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2023 & 2030

EUROPE

Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)

Europe Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR

Europe Historic Review for Premature Ejaculation Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Europe 16-Year Perspective for Premature Ejaculation Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030

Europe Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Europe Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Europe 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2023 & 2030

Europe Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Europe Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Europe 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2023 & 2030

FRANCE

Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)

France Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

France Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

France 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2023 & 2030

France Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

France Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

France 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2023 & 2030

GERMANY

Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)

Germany Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Germany Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Germany 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2023 & 2030

Germany Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Germany Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Germany 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2023 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Italy Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Italy 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2023 & 2030

Italy Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Italy Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Italy 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2023 & 2030

UNITED KINGDOM

Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)

UK Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

UK Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

UK 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2023 & 2030

UK Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

UK Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

UK 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2023 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Rest of Europe Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Rest of Europe 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2023 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Rest of Europe Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Rest of Europe 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2023 & 2030

ASIA-PACIFIC

Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Asia-Pacific Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Asia-Pacific 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2023 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Asia-Pacific Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Asia-Pacific 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2023 & 2030

REST OF WORLD

Rest of World Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Rest of World Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Rest of World 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2023 & 2030

Rest of World Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR

Rest of World Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Rest of World 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2023 & 2030

IV. COMPETITION

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
Boston Medical Group	%
IXCHELSIS Ltd	%
Plethora Solutions	%
Virility Medical	%

* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.